Examining the Inclusivity of US Trials of COVID-19 Treatment.

The urgency of the COVID-19 pandemic has increased attention on the need to include patients traditionally underrepresented in research, especially people with comorbid diseases, racial/ethnic minorities, pregnant/lactating women, and children.1–4 We characterized the inclusion and exclusion criteria of US COVID-19 treatment trials to understand their applicability to highly affected populations and groups traditionally underrepresented in research.